This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

China's Sichuan Xieli Pharmaceutical fined for obstructing antitrust probe

( May 26, 2025, 03:42 GMT | Official Statement) -- MLex Summary: China's Sichuan Xieli Pharmaceutical Company has been fined 2,790,700 yuan ($389,000) — equivalent to 0.8 percent of its 2022 sales — by the Jiangsu Provincial Market Regulator for violently impeding an antitrust investigation conducted by the regulator. The company's legal representative, two employees and three staff members from a related company also faced fines ranging from 200,000 to 400,000 yuan each for obstructing the probe, including concealing their whereabouts and breaking computers during a November 2023 on-site investigation. The case centers on a monopoly involving a domestic pharmaceutical ingredient during the late-2022 adjustment to epidemic prevention policies, which led to a tight supply of critical drugs. The statement follows and penalty decisions are attached:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login